Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase Ⅰ and topoisomerase Ⅱ

OBJECTIVE The aim of this study is to investigate the inhibitory effects of lapachol on rat C6 glioma both in vitro and in vivo,as well as the potential mechanisms.METHODS First,the model of C6 glioma in Wistar rats was established and verified by hemotoxylin and eosin staining,immunohistochemical staining and magnetic resonance imaging(MRI).Then different doses of lapachol were gavaged and tumor volumes of the C6 glioma were detected by MRI.The effects of lapachol on C6 cell proliferation,apoptosis and DNA damage were detected by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium(MTS)/phen-azinemethosulfate(PMS)assay,Hoechst33358 staining,AnnexinⅤ-FITC/PI staining,and comet assay.Effects of lapachol on topoisomeraseⅠ(TOPⅠ)and topoisomeraseⅡ(TOPⅡ)activities were detected by TOPⅠand TOPⅡmediated supercoiled p BR322 DNA relaxation assay.Molecular docking was used to predict the interaction of lapachol-TOPⅠand lapachol-TOPⅡ.TOP I and TOPⅡexpression levels in C6 cells were determined by Enzymelinked immunosorbent assay kits and real-time polymerase chain reaction(RT-PCR).RESULTS The rat C6 glioma model was successfully established.High dose lapachol showed significant inhibitory effect on the C6 glioma in Wistar rats(P<0.05).MTS/PMS assay,Hoechst 33258 staining,AnnexinⅤ-FITC/PI staining,and comet assay showed that lapachol could inhibit proliferation,induce apoptosis and DNA damage of C6 cells in dose dependent manners.Lapachol could inhibit the activities of both TOPⅠandⅡ.Molecular docking showed that lapachol-TOPⅠshowed relatively stronger interaction than that of lapachol-TOPⅡ.Enzyme-linked immunosorbent assay and RT-PCR showed that lapachol could inhibit TOPⅡexpression levels,but not TOPⅠexpression levels.CONCLUSION These results showed that lapachol could significantly inhibit C6 glioma both in vivo and in vitro,which might be related with inhibiting TOPⅠand TOPⅡactivities,as wel as TOPⅡexpression.

Discovery of a series of pyridopyrimidine derivatives as potential topoisomerase Ⅰ inhibitors

A series of new 3-benzoheterocyclic substituted pyridopyrimidines were designed and synthesized. Structures of the compounds were determined by IR, 1H NMR, and elemental analyses. The anti- proliferation activity of 13 novel compounds was evaluated in A549, HL-60, BGC-823 and SMMC-7721 cell lines. Compounds 3, 5, 7, 8, 9,10 showed potent inhibitory activity against the four tested cancer cell lines. These six compounds were examined for Top I inhibition at 100 μmol/L by measuring the relaxation of supercoiled DNA in plasmid pBR322. Most of the tested compounds inhibited the enzyme at this concentration. The most potent compound 9 was as potent as camptothecin.

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomeraseⅠ and topoisomeraseⅡ

OBJECTIVE Lapachol is a natural naphthoquinone compound that possesses extensive biological activities.The aim of this study is to investigate the inhibitory effects of lapachol on rat C6 glioma both in vitro and in vivo,as well as the potential mechanisms.METHODS The antitumor effect of lapachol was firstly evaluated in the C6 glioma model in Wistar rats.The effects of lapachol on C6 cell proliferation,apoptosis and DNA damage were detected by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium(MTS)/phenazinemethosulfate(PMS)assay,hoechst 33358 staining,annexinⅤ-FITC/PI staining,and comet assay.Effects of lapachol on topoisomerase I(TOP I)and topoisomeraseⅡ(TOPⅡ)activities were detected by TOPⅠand TOPⅡmediated supercoiled p BR322DNA relaxation assays and molecular docking.TOPⅠand TOPⅡexpression levels in C6 cells were also determined.RESULTS High dose lapachol showed significant inhibitory effect on the C6 glioma in Wistar rats(P<0.05).It was showed that lapachol could inhibit proliferation,induce apoptosis and DNA damage of C6 cel s in dose dependent manners.Lapachol could inhibit the activities of both TOPⅠ and Ⅱ.Lapachol-TOPⅠshowed relatively stronger interaction than that of lapachol-TOPⅡin molecular docking study.Also,lapachol could inhibit TOPⅡexpression levels,but not TOPⅠexpression levels.CONCLUSION These results showed that lapachol could significantly inhibit C6 glioma both in vivo and in vitro,which might be related with inhibiting TOPⅠ and TOPⅡ activities,as wel as TOPⅡ expression.

Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model

AIM:rAAV mediated endostatin gene therapy has been examined as a new method for treating cancer.However, a sustained and high protein delivery is required to achieve the desired therapeutic effects.We evaluated the impact of topoisomerase inhibitors in rAAV delivered endostatin gene therapy in a liver tumor model. METHODS:rAAV containing endostatin expression cassettes were transduced into hepatoma cell lines.To test whether the topoisomerase inhibitor pretreatment increased the expression of endostatin,Western blotting and ELISA were performed.The biologic activity of endostatin was confirmed by endothelial cell proliferation and tube formation assays. The anti-tumor effects of the rAAV-endostatin vector combined with a topoisomerase inhibitor,etoposide,were evaluated in a mouse liver tumor model. RESULTS:Topoisomerase inhibitors,including camptothecin and etoposide,were found to increase the endostatin exPression level in vitro.The over-expressed endostatin, as a result of pretreatment with a topoisomerase inhibitor, was also biologically active.In animal experiments,the combined therapy of topoisomerase inhibitor,etoposide with the rAAV-endostatin vector had the best tumor- suppressive effect and tumor foci were barely observed in livers of the treated mice.Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice.Finally,the mice treated With rAAV-endostatin in combination with etoposide showed the longest survival among the experimental models. CONCLUSION:rAAV delivered endostatin gene therapy in combination with a topoisomerase inhibitor pretreatment is an effective modality for anticancer gene therapy.

Calpain inhibitorⅠ对糖皮质激素受体表达和转录激活作用的影响

目的 探讨CalpaininhibitorⅠ对糖皮质激素受体 (glucocorticoidreceptor ,GR)表达和转录激活作用的影响。方法 Raw 2 64 .7细胞经地塞米松、CalpaininhibitorⅠ或两者共同处理 12h ,观察糖皮质激素受体表达水平的变化。质粒PRsh GRα和报告质粒pMAMneo CAT转入COS 7细胞 ,观察CalpaininhibitorⅠ对糖皮质激素受体转录激活作用的影响。结果 Raw 2 64 .7细胞经地塞米松处理 12h后GR蛋白条带减弱 ,提示地塞米松可诱导GR表达下调 ,而CalpaininhibitorⅠ可以部分抑制此作用。共转染实验表明CalpaininhibitorⅠ可增强地塞米松对GR的转录激活作用。结论 CalpaininhibitorⅠ可抑制糖皮质激素受体 (激素依赖性受体 )下调 ,并可增强GR的转录激活作用。

PhaseⅠdose-escalation and expansion study of PARP inhibitor,fluzoparib(SHR3162),in patients with advanced solid tumors

Objective:Fluzoparib(SHR3162)is a novel,potent poly(ADP-ribose)polymerases(PARP)1,2 inhibitor that showed anti-tumor activity in xenograft models.We conducted a phaseⅠ,first-in-human,dose-escalation and expansion(D-Esc and D-Ex)trial in patients with advanced solid cancer.Methods:This was a 3+3 phaseⅠD-Esc trial with a 3-level D-Ex at 5 hospitals in China.Eligible patients for DEsc had advanced solid tumors refractory to standard therapies,and D-Ex enrolled patients with ovarian cancer(OC).Fluzoparib was administered orally once or twice daily(bid)at 11 dose levels from 10 to 400 mg/d.Endpoints included dose-finding,safety,pharmacokinetics,and antitumor activity.Results:Seventy-nine patients were enrolled from March,2015 to January,2018[OC(47,59.5%);breast cancer(BC)(16,20.3%);colorectal cancer(8,10.1%),other tumors(8,10.1%)];48 patients were treated in the D-Esc arm and 31 in the D-Ex arm.The maximum tolerated dose(MTD)was 150 mg bid,with a half-life of 9.14 h.Grade 3/4 adverse events included anemia(7.6%)and neutropenia(5.1%).The objective response rate(ORR)was 30%(3/10)in patients with platinum-sensitive OC and 7.7%(1/13)in patients with BC.Among patients treated with fluzoparib≥120 mg/d,median progression-free survival(m PFS)was 7.2[95%confidence interval(95%CI),1.8-9.3]months in OC,9.3(95%CI,7.2-9.3)months in platinum-sensitive OC,and 3.5(range,2.0-28.0)months in BC.In patients with germline BC susceptibility gene mutation(g BRCAMut)(11/43 OC;2/16 BC),m PFS was 8.9 months for OC(range,1.0-23.2;95%CI,1.0-16.8)and 14 and 28 months for BC(those two patients both also had somatic BRCAMut).Conclusions:The MTD of fluzoparib was 150 mg bid in advanced solid malignancies.Fluzoparib demonstrated single-agent antitumor activity in BC and OC,particularly in BRCAMut and platinum-sensitive OC.

Protein Flexibility and Multiple Docking in Ligand Docking and Virtual Screening to the BRAF(TypeⅠ1/2)Inhibitors

BRAF has been recognized as a promising target for cancer therapy. A number of crystal structures have been published. Molecular docking is one of the most effective techniques in the field of computer-aided drug design（CADD）. Appropriate protein conformation and docking method are essential for the successful virtual screening experiments. One approach considering protein flexibility and multiple docking methods was proposed in this study. Six DFG-in/αC-helix-out crystal structures of BRAF, three docking programs（Glide, GOLD and Ligand Fit） and 12 scoring functions were applied for the best combination by judging from the results of pose prediction and retrospective virtual screening（VS）. The most accurate results（mean RMSD of about 0.6 A） of pose prediction were obtained with two complex structures（PDB： 3 C4 C and 3 SKC） using Glide SP. From the retrospective VS, the most active compounds were identified by using the complex structure of 3 SKC, indicated by a ROC/AUC score of 0.998 and an EF of 20.6 at 5% of the database screen with Glide-SP. On the whole, PDB 3 SKC could achieve a higher rate of correct reproduction, a better enrichment and more diverse compounds. A comparison of 3 SKC and the other X-ray crystal structures led to a rationale for the docking results. PDB 3 SKC could achieve a broad range of sulfonamide substitutions through an expanded hydrophobic pocket formed by a further shift of the αC-helix. Our study emphasized the necessity and significance of protein flexibility and scoring functions in both ligand docking and virtual screening.

以重组人DNA拓扑异构酶Ⅰ为靶位从天然产物及其衍生物中筛选抗肿瘤化合物

为了在体外以人DNA拓扑异构酶Ⅰ(hTopoⅠ)为靶位进行抗肿瘤化合物的快速筛选,首次使用毕赤酵母表达了hTopoⅠ。在微量反应体系中,测定了化合物抑制hTopoⅠ松驰活性的能力,并用MTT实验验证筛选到的hTopoⅠ抑制剂的抗肿瘤活性。从74个结构新颖的天然产物及人工合成的黄酮类衍生物中筛到6个hTopoⅠ抑制剂,有4个化合物抑制肿瘤细胞生长的能力较强。

拓扑异构酶Ⅰ抑制剂研究进展

拓扑异构酶Ⅰ(topoisomeraseⅠ,TopoⅠ)是抗肿瘤研究的重要靶点,以TopoⅠ为靶点的药物在肿瘤化疗中被广泛应用。目前临床使用或处于临床前研究的拓扑异构酶Ⅰ抑制剂主要分为喜树碱类(camptothecin,CPT)和非喜树碱类(non-camptothecin TopoⅠinhibitor)化合物。本文主要介绍了近年来TopoⅠ抑制剂研发领域的最新进展和发展趋势,并重点就近年来涌现出的一些新的TopoⅠ抑制剂的抗肿瘤活性和药理学特性做一综述。

拓扑异构酶Ⅰ抑制剂研究进展

拓扑异构酶Ⅰ(topoisomerase,Topo)参与DNA复制、转录、重组、修复等所有关键的细胞核内过程,是抗肿瘤研究的重要靶点,以TopoⅠ为靶点的药物在肿瘤化疗中被广泛应用。目前临床使用或处于临床前研究的拓扑异构酶Ⅰ抑制剂主要分为喜树碱类和非喜树碱类化合物。该文主要介绍了近年来TopoⅠ抑制剂研发领域的最新进展和发展趋势,并就近年来涌现出的一些新的TopoⅠ抑制剂的抗肿瘤活性和药理学特性做一总结。

抗癌新药——拓扑异构酶Ⅰ抑制剂

目的：阐述３种拓扑异构酶Ⅰ抑制剂，依莲洛特肯、拓扑特肯及９氨基喜树碱的药理及临床疗效。方法：用经典的临床前及临床试验方法。结果：①依莲洛特肯（ＣＰＴ１１）体内转变为ＳＮ３８而显效。对小鼠Ｓ１８０，Ｌｅｗｉｓ肺癌、胰癌Ｏ３、黑色素瘤Ｂ１６、结肠癌３８及多种人癌裸鼠移植瘤均有良效。用量１００ｍｇ／（ｍ２·周）或３５０ｍｇ／（ｍ２·３周）。临床上对非小细胞肺癌（ＮＳＣＬＣ）、结直肠癌、卵巢癌、淋巴瘤类等有效，合用药物常为顺铂（ＤＤＰ）、鬼臼乙叉甙（ＶＰ１６）、紫杉醇等。不良反应主要是骨髓抑制及下泻。②拓扑特肯（ＴＰＴ），其下泻副作用可用洛哌胺纠正。多用１．５ｍｇ／（ｍ２·ｄ）×５静滴。临床上对ＮＳＣＬＣ、前列腺癌、卵巢癌、结直肠癌等有效。③９氨基喜树碱（９ＡＣ），研究刚开始。结论：喜树碱衍化物具拓扑异构酶Ⅰ抑制作用，是有希望的抗癌药物。

2种喜树碱类拓扑异构酶1抑制剂ADE信号的挖掘与分析

目的对2种喜树碱类拓扑异构酶1抑制剂伊立替康和托泊替康的药物不良事件(ADE)信号进行挖掘与分析,为临床安全用药提供参考。方法基于美国FDA不良事件报告系统(FAERS)数据库,提取2004年1月1日至2023年3月31日上述2种药物的ADE报告数据。对数据进行处理后,采用报告比值比法联合贝叶斯置信传播神经网络法进行信号挖掘,并进行分析。结果共筛选出相关ADE报告14738份,其中伊立替康11483份,托泊替康3255份。伊立替康的ADE报告性别以男性为主,托泊替康以女性为主;两药的使用患者年龄均主要集中于45~<75岁。共检测出847个信号,累及24个系统器官分类(SOC)。其中,伊立替康检测出565个信号,累及24个SOC,主要集中于胃肠系统疾病、全身性疾病及给药部位各种反应、血液及淋巴系统疾病等;报告频数最多的ADE为腹泻,信号强度最大的ADE为胆碱能综合征。托泊替康检测出282个信号,累及22个SOC,主要集中于全身性疾病及给药部位各种反应、各类检查、血液及淋巴系统疾病、胃肠系统疾病等;报告频数较多的ADE为死亡和贫血,信号强度最大的ADE为发热性骨髓再生障碍。伊立替康的转移性结肠直肠癌、外周感觉神经病、脂肪性肝炎等ADE和托泊替康的虹膜萎缩、视网膜变性、玻璃体积血等ADE均未在各自说明书中提及。结论伊立替康和托泊替康的ADE主要累及消化系统和血液系统,临床上应重点监测;伊立替康所引起的胆碱能综合征应引起关注。除此之外,使用伊立替康的患者还应关注转移性结肠直肠癌、外周感觉神经病、脂肪性肝炎、蛋白尿等ADE,使用托泊替康的患者应加强眼器官疾病的监测,以确保用药安全。

疡愈涂剂对糖尿病大鼠创面Ⅰ、Ⅲ胶原合成及MMPs、TIMP-1表达的影响

目的:观察疡愈涂剂促进糖尿病迟缓愈合伤口的修复作用及其分子机制。方法:实验分为对照组、模型组、疡愈涂剂高、中、低剂量组。除对照组外,大鼠腹腔注射链脲佐菌素(STZ)55mg/kg,造成实验性高血糖。30d后,各组动物复合背部全厚皮切除直径为1·6cm的伤口。分别观察疡愈涂剂对创面愈合时间、愈合率的影响;天狼星红染色法以及免疫组化法观察Ⅰ、Ⅲ型胶原含量及Ⅰ、Ⅲ型胶原比值,并观察金属蛋白酶-1、-13(MMP-1、-13)、金属蛋白酶抑制剂-1(TIMP-1)水平及MMP-1、-13与TIMP-1比值。结果:疡愈涂剂各剂量组创面愈合时间明显短于模型组(P<0·01),愈合率明显高于模型组(P<0·01,P<0·05)。在伤口用药的第3、7、11d,高、中剂量组创面Ⅰ型胶原含量以及Ⅰ、Ⅲ型胶原比值显著高于模型组(P<0·01)。在伤口用药第3d疡愈涂剂中剂量、第7、11d各剂量组创面Ⅲ型胶原显著高于模型组(P<0·01)。各剂量组在第7d创面MMP-1、-13均高于模型组(P<0·01,P<0·05),而MMP-1在第11d与模型组趋于一致且MMP-13明显低于模型组(P<0·01,P<0·05)。各剂量组在3、7、11d创面TIMP-1均明显高于模型组(P<0·01,P<0·05),在第11d各剂量组MMP-1、TIMP-1比值明显低于模型组(P<0·01),在第3、7d高、中剂量组创面MMP-13、TIMP-1比值高于模型组(P<0·01),而到第11d高、中、低各剂量组均明显低于模型组(P<0·01);第11d高、中剂量组MMP-13、TIMP-1比值低于低剂量组(P<0·05)。结论:疡愈涂剂可能通过调节影响胶原代谢的MMPs、TIMPs表达平衡,促进胶原的合成和沉积,从而加速创面的愈合。

线粒体复合体Ⅰ呼吸抑制剂的研究

线粒体复合体Ⅰ呼吸抑制剂不仅在医药上有着重要的研究价值,在农药方面也有着特殊的意义。这类药剂的作用机制比较特殊,害虫不易产生抗性,是一类非常有前途的杀虫药剂。从植物,微生物等生物体中发现了许多线粒体复合体Ⅰ呼吸抑制剂,如鱼藤酮、粉蝶霉素A、辣椒碱,番荔枝内酯、myxalamid等,它们可以作为农药的先导化合物进行药物合成。根据不同的作用方式,线粒体复合体Ⅰ呼吸抑制剂可分3种类型,分别以粉蝶霉素A、鱼藤酮、辣椒碱为代表。

枸橼酸爱地那非片Ⅰ期临床耐受性研究

目的：观察枸橼酸爱地那非片在健康人体的安全性和耐受性。方法：单次给药试验共入选28例健康男性志愿者，随机分为4个剂量组，由初始剂量30mg开始，在耐受性较好的情况下，逐渐增加至60，90，120mg。连续给药试验在单次给药试验结束后进行，共入选36例健康男性志愿者，随机分为3个剂量组，递增剂量分别为30，45，60mg，qd，连续3d。观察临床症状体征并严密观察记录试验期间发生的不良事件。结果：单次给药试验与研究药物有关的不良事件主要为视觉异常（发生率35．7％），面色潮红（发生率21．4％），头痛或头晕（发生率17．9％）等；连续给药试验与研究药物有关的不良事件为面色潮红（发生率7．4％），头痛或头晕（发生率7．4％）。试验中未发生严重不良事件，所有不良事件的程度均为轻度，均未经处理均自行消失。给药后生命体征、实验室检查和眼科检查均未见有临床意义的改变。结论：中国男性健康受试者单次口服30～120mg的枸橼酸爱地那非片和连续3d，30～60mg qd的枸橼酸爱地那非片安全耐受。

乳腺癌组织中MMP-2、TIMP-2、TGF-β_1、TGF-β_1RⅠ的表达及相关性分析

目的探讨基质金属蛋白酶(MMP)-2及其抑制物(TIMP-2)与转化生长因子(TGF)-β1及其I型受体(TGF-β1RI)在乳腺癌组织中的表达及其相关性。方法应用免疫组化SP法检测80例乳腺癌组织中的MMP-2、TIMP-2与TGF-β1、TGF-β1RI蛋白。结果乳腺癌中MMP-2、TIMP-2、TGF-β1和TGF-β1RI阳性表达率分别为67.5%、45.0%、80.0%和67.5%;无淋巴结转移者MMP-2、TIMP-2阳性表达率为44.4%、66.7%,与转移淋巴结个数1～3(85.7%、21.4%)、>3个(87.5%、37.5%)相比,P均<0.01;TNM分期为Ⅰ期的MMP-2、TIMP-2阳性表达率分别为0、75%,分别与Ⅱ(65.0%、55.0%)、Ⅲ(86.7%、26.7%)、Ⅳ期(100%、0)相比,P均<0.05;肿瘤直径≤2cm者TIMP-2阳性表达率为66.7%,与直径2～5(51.9%)、>5cm(20.0%)相比,P均<0.05;MMP-2和TGF-β1的表达呈正相关(r=0.454,P<0.01),MMP-2和TGF-β1RI的表达呈负相关(r=-0.481,P<0.01)。结论MMP-2和TIMP-2的表达情况与乳腺癌侵袭转移有密切关系。MMP-2的表达与TGF-β1、TGF-β1RI关系密切,MMP-2可能在一定程度上受到TGF-β及其受体的调控。

血管紧张素Ⅰ转换酶、血浆纤溶酶原激活物抑制剂基因多态性与2型糖尿病肾病相关性分析

目的探讨血管紧张素Ⅰ转换酶（ACE）、血浆纤溶酶原激活物抑制剂（PAI-1）基因多态性与2型糖尿病肾病的相关性。方法58例健康者为对照组、92例糖尿病非肾病患者为糖尿病非肾病组、125例糖尿病肾病患者为糖尿病肾病组，聚合酶链反应确定ACE、PAI-1基因型。酶联免疫吸附法检测血浆PAI-1。结果糖尿病肾病组ACE基因中D等位基因频率、PAI-1基因中4G等位基因频率明显高于糖尿病非肾病组、对照组。Logistic回归分析表明ACE、PAI-1基因是2型糖尿病肾病的危险因素。结论ACE基因中D等位基因、PAI-1基因中4G等位基因可能涉及2型糖尿病肾病发病。

实验性肝纤维化时MMP-1、TIMP-1的表达与Ⅰ、Ⅲ型胶原含量变化的关系

为了观察实验性肝纤维化时MMP - 1、TIMP - 1的表达与Ⅰ、Ⅲ型胶原含量变化之间的关系 ,本文制备了免疫性大鼠肝纤维化模型 ,运用定量RT -PCR检测肝脏内MMP - 1、TIMP - 1的表达 ,通过免疫组化检测肝组织中Ⅰ、Ⅲ型胶原的含量。运用相关理论作统计学分析。结果发现在肝纤维化发生时 ,Ⅰ型胶原和Ⅲ型胶原含量的变化有显著相关性 ;MMP - 1的表达在肝纤维化组与正常对照组之间未见显著差异 ,与Ⅰ、Ⅲ型胶原的含量变化之间也未见有相关性 ;TIMP - 1的表达在肝纤维化发生时显著增高 ,与Ⅰ、Ⅲ型胶原的变化也有显著相关性。结果表明肝纤维化发生时MMP - 1的表达未见明显改变 ,而TIMP - 1的表达显著增高 ,且与Ⅰ、Ⅲ型胶原含量的增高呈显著相关 ,提示TIMP - 1的表达增高在肝纤维化的发生。

抗纤复方药物血清对HSC-LI90细胞Ⅰ型、Ⅳ型前胶原和基质金属蛋白酶及其组织抑制因子-1基因表达的影响

目的 :探讨抗纤复方药物血清对肝星形细胞 (HSC)LI90细胞 (HSC LI90 )Ⅰ型、Ⅳ型前胶原和基质金属蛋白酶 (MMPs)及其组织抑制因子 (TIMP 1)基因表达的影响。方法 :以 0 5、2 0、4 0 g/kg等不同剂量抗纤复方灌胃大鼠 ,制备药物血清 ,作用于HSC LI90细胞 4 8h ,应用Northern印迹杂交的方法 ,检测Ⅰ型、Ⅳ型前胶原、基质金属蛋白酶 2 (MMP 2 )及膜型基质金属蛋白酶 (MT1 MMP)及其组织抑制因子(TIMP 1)基因的表达 ,并用酶图法检测基质金属蛋白酶 2的活性。结果 :(1)抗纤复方不同浓度药物血清能抑制HSC LI90细胞Ⅰ型、Ⅳ型前胶原及其组织抑制因子TIMP 1的基因表达 (P <0 0 5或P <0 0 1) ;(2 )能增加膜型基质金属蛋白酶基因表达 (P <0 0 1) ;(3)对基质金属蛋白酶 2基因表达及活性无影响 (P >0 0 5 )。结论 :(1)抗纤复方具有抗肝纤维化作用 ;(2 )抗纤复方抑制HSC LI90细胞TIMP 1基因表达水平 ,促进胶原降解 ,可能是抗肝纤维化的作用机制之一。